Optimal Use of Fluoroquinolones in the Intensive Care Unit Setting (Q37818799)

23 August 2017

1 reference

title

Optimal use of fluoroquinolones in the intensive care unit setting (English)

1 reference

23 August 2017

Optimal Use of Fluoroquinolones in the Intensive Care Unit Setting (English)

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

19 November 2024

1 reference

John C. Rotschafer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21144988

19 November 2024

Mary A. Ullman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21144988

19 November 2024

Christopher J. Sullivan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21144988

19 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21144988

19 November 2024

publication date

1 January 2011

1 reference

23 August 2017

January 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21144988

full work available at URL

19 November 2024

http://www.criticalcare.theclinics.com/article/S0749070410001028/pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21144988

https://api.elsevier.com/content/article/PII:S0749070410001028?httpAccept=text/xml

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

https://api.elsevier.com/content/article/PII:S0749070410001028?httpAccept=text/plain

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

19 November 2024

published in

Critical Care Clinics

1 reference

23 August 2017

volume

27

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

95-106

1 reference

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials

19 November 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Escherichia coli resistance to quinolones at a comprehensive cancer center

19 November 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Mechanochemical analysis of DNA gyrase using rotor bead tracking

19 November 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

DNA topoisomerases: structure, function, and mechanism

19 November 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Cellular roles of dna topoisomerases: a molecular perspective

19 November 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients

19 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Nosocomial spread of ESBL-positive Enterobacter cloacae co-expressing plasmid-mediated quinolone resistance Qnr determinants in one hospital in France

19 November 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Application of fluoroquinolone pharmacodynamics

19 November 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm?

19 November 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure

19 November 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model

19 November 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis

19 November 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM.

19 November 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy

19 November 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus

19 November 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Quinolone resistance from a transferable plasmid.

19 November 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Pharmacotherapy and pharmacodynamics in the management of bacterial infection

19 November 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Optimizing use of quinolones in the critically ill.

19 November 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

19 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

19 November 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

19 November 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

19 November 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

19 November 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group

19 November 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia

19 November 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

19 November 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia

19 November 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia

19 November 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome.

19 November 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia

19 November 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

19 November 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CCC.2010.11.005

19 November 2024

Identifiers

1 reference

23 August 2017

1 reference